Skip to main content

Capital Raising Seminar Series Part 1: Funding Sources for Private Companies

Feb
7
2017

Date: February 7, 2017

Time: 2:30AM - 4:00AM

Location: San Diego, CA

Mintz Levin is hosting a three-part series focused on financing for life sciences companies from initial funding to IPO via private sources, non-traditional IPOs, and traditional IPOs.  Mintz Levin attorneys, Jeremy Glaser and Bill Whelan, will be joined by Barbara McClung, Chief Legal Officer and Corporate Secretary, Caribou Biosciences and Mark Lappe, CEO, INHIBRx  to share insights into the private capital raising process.

Our first session will focus on financing sources for private life sciences, medical device, medical technology, and health IT companies, including angel funding, joint development, strategic investors, and venture capital. A panel of entrepreneurs, in-house counsel, and advisors will share best practices and practical considerations to prepare companies for raising their first, or next, round of capital, including:

  • Best practices for raising capital, including important legal considerations
  • Common legal pitfalls and how to avoid them

  • What to expect and plan for at each stage of funding

  • Negotiating and drafting term sheets

CEOs, CFOs, in-house counsel,  and service providers will benefit from this discussion of current best practices and trends.

Please also join us for Parts 2 & 3!

Tuesday, May 9, 2017: Going Public Through a Non-Traditional IPO

Tuesday, September 12, 2017: Going Public through a Traditional IPO

All seminars will be held in Mintz Levin's San Diego Office.

Speakers

William T. Whelan is a Mintz Member who counsels life science companies on venture capital financing and mergers and acquisitions. Bill guides clients through every stage of the corporate life cycle. He works with biotechnology, medical technology, and health care IT companies.
Jeremy D. Glaser is Co-chair of Mintz's Venture Capital & Emerging Companies Practice. He has over three decades of experience guiding life sciences and technology companies in growth and financing strategies, including public offerings, financings, mergers and acquisitions, and SEC compliance.